| 000 | 01726 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513195012.0 | ||
| 264 | 0 | _c20000113 | |
| 008 | 200001s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.1999.17.6.1939 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChlebowski, R T | |
| 245 | 0 | 0 |
_aAmerican Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cJun 1999 |
||
| 300 |
_a1939-55 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAnticarcinogenic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 |
_aBreast Neoplasms _xepidemiology |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xepidemiology |
| 650 | 0 | 4 |
_aCataract _xepidemiology |
| 650 | 0 | 4 |
_aEndometrial Neoplasms _xchemically induced |
| 650 | 0 | 4 |
_aEstrogen Antagonists _xadverse effects |
| 650 | 0 | 4 | _aExpert Testimony |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aMenopause _xdrug effects |
| 650 | 0 | 4 |
_aRaloxifene Hydrochloride _xadverse effects |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aTamoxifen _xadverse effects |
| 700 | 1 | _aCollyar, D E | |
| 700 | 1 | _aSomerfield, M R | |
| 700 | 1 | _aPfister, D G | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 17 _gno. 6 _gp. 1939-55 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.1999.17.6.1939 _zAvailable from publisher's website |
| 999 |
_c10517561 _d10517561 |
||